Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 7/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602330 | 1.00 | PREP (0.43) | PREPSIGMAR1USP19GRIN2BHRH3 | |
| SCHEMBL31671847 | 0.79 | EPHX2 (0.36) | USP19HRH3PAX8 | |
| SCHEMBL31671495 | 0.79 | EPHX2 (0.36) | USP19HRH3PAX8 | |
| SCHEMBL26564248 | 0.73 | SIGMAR1 (0.45) | PREPSIGMAR1USP19HRH3 | |
| SCHEMBL26564145 | 0.73 | SIGMAR1 (0.45) | PREPSIGMAR1USP19HRH3 | |
| SCHEMBL8164614 | 0.72 | ALDH1A1 (0.53) | GRIN2BNPC1RAB9A | |
| SCHEMBL3607182 | 0.72 | ALDH1A1 (0.53) | GRIN2BNPC1RAB9A | |
| SCHEMBL26567145 | 0.72 | LMNA (0.46) | PREPSIGMAR1USP19HRH3 | |
| SCHEMBL26564141 | 0.72 | LMNA (0.46) | PREPSIGMAR1USP19HRH3 | |
| SCHEMBL26568645 | 0.71 | LMNA (0.44) | PREPSIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2121612-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | PREP 1214/4885SIGMAR1 1201/4885USP19 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.